Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

JHL Starts European Trial of MabThera/Rituxan Biosimilar for RA

publication date: Mar 29, 2017
JHL Biotech has dosed the first patient in a European trial of JHL1101, a biosimilar to the Roche/Genentech rheumatoid arthritis treatment MabThera/Rituxan. JHL is a Taiwan-China biotech, formed by Genentech veterans, with a Wuhan, China manufacturing facility that is compliant with international regulations. Late in 2016, JHL struck a deal with Sanofi giving Sanofi rights to commercialize JHL1101 in China (though no trials have been announced). Sanofi paid $21 million upfront and invested $80 million in JHL stock for the rights in a deal valued at $257 million. More details....

Stock Symbols: (TWO: 6540) (NYSE: SNY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital